Hagen Kennecke, M.D., M.H.A., FRCPC (he/him)

Biography

Dr. Hagen Kennecke is Professor of Medicine and a gastrointestinal medical oncologist at Oregon Health & Science University’s Knight Cancer Institute. He serves as Executive Officer of the SWOG Cancer Research Network. His clinical and research work focuses on colon and rectal cancers and neuroendocrine tumors, with an emphasis on improving outcomes through clinical trials, personalized treatment and multidisciplinary care.

He has more than two decades of clinical trial experience, including leadership of investigator-initiated studies, cooperative group trials and industry-sponsored research. His work spans early-phase drug development, randomized phase II and III trials, translational biomarker studies and population-based outcomes research. He chaired the phase II NEO trial (CCTG CO.28) and chairs the international phase III NEO-RT trial (CCTG CO.32), investigating organ preservation in early rectal cancer. His broader research includes neoadjuvant treatment strategies, molecular predictors of response, circulating tumor DNA, hepatic artery infusion approaches and radioligand therapy combinations for neuroendocrine tumors.

Dr. Kennecke has an extensive history of securing competitive academic grants and industry-sponsored research funding as a principal investigator and collaborating investigator. His funding portfolio includes support from NIH/NCI, the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, cancer foundations and patient advocacy organizations, as well as numerous pharmaceutical and biotechnology sponsors. These grants and contracts have supported clinical trials, molecular diagnostics, research databases and collaborative research programs in gastrointestinal oncology.

He is a past chair of the NCI Rectal-Anal Task Force, co-chairs the SWOG Rectal-Anal Cancer Subcommittee and chairs the NANETS Rectal Neuroendocrine Tumor Guidelines Committee. He contributes to national clinical practice guidelines through ASCO and NANETS and serves on the NCI Gastrointestinal Cancer Steering Committee.

Education and training

  • Degrees

    • M.D., Dalhouse University
    • M.H.A., University of British Columbia
    • B.Sc., University of British Columbia
  • Residency

    • Internal Medicine, Legacy Health Systems, Portland, OR
  • Fellowship

    • Medical Oncology, University of British Columbia, Vancouver, British Columbia, Canada
  • Certifications

    • Fellow of the Royal College of Physicians of Canada, Internal Medicine, Medical Oncology
    • American Board of Internal Medicine, Internal Medicine

Memberships and associations:

  • American Society of Clinical Oncology (ASCO)
  • SWOG Cancer Research Network
  • Canadian Cancer Trials Group (CCTG)
  • North American Neuroendocrine Tumor Society (NANETS)

Publications

Selected publications

  • Kennecke HF, Brown CJ, Whiteford MH, Nurkin S, Cann CC, VanderWalde NA, Cohen SA, Loree JM, Hall WA, Dennis K, Horowitz DP. NEO-RT organ preservation trial for early rectal cancer: CCTG CO. 32 phase III randomized trial of neoadjuvant chemotherapy, excision and observation versus chemoradiotherapy. JCO Oncology Advances. 2026 Mar;3(1):e2500176.
  • Kendsersky ND, Erlick MR, Chen EY, Kennecke HF. The Evolving Role for Repeat Molecular Testing in Metastatic Colorectal Cancer. Cancers. 2026 Mar 20;18(6):1007.
  • Loree JM, Titmuss E, Brown CJ, Rich T, Banks K, Gordon V, Patel S, Krahn M, Caycedo-Marulanda A, Raval M, Tu D. HF Kennecke Tumor-Free Circulating Tumor DNA in Node-Negative Rectal Cancers Undergoing Neoadjuvant Chemotherapy, Excision, and Observation in the Phase II NEO Trial (CO. 28). JCO Precision Oncology. 2026 Oct;10(10):e2600459.
  • Kennecke H, Delpassand E, Felder S, Gleeson F, Hallet J, Horowitz D, Hyrcza M, Katona BW, Kiely M, Kim M, Mallak N. NANETS Guidelines for the diagnosis and management of stage I–III rectal neuroendocrine tumors. Endocrine-Related Cancer. 2026 Feb 1;33(2).
  • Chen EY, Nabavizadeh N, Kendsersky ND, Lessenich C, Herzig DO, Korngold E, Goodyear SM, Kennecke HF, Kardosh A, Tsikitis VL, Lu K. Phase 1b study to assess the safety of neoadjuvant trifluridine/tipiracil with concurrent radiation in resectable stage II/III rectal cancer: the FIERCE study. Clinical Colorectal Cancer. 2026 Feb 4.
  • Scott AJ, Kennedy EB, Berlin J, Kachnic L, Kennecke HF, Gholami S. Management of Locally Advanced Rectal Cancer: ASCO Guideline Clinical Insights. JCO Oncology Practice. 2025 Mar;21(3):281-6.
  • Morris VK, Kennedy EB, Amin MA, Aranha O, Benson III AB, Dorth JA, Horowitz DP, Kennecke HF, Kim S, Kreppel L, Mettu NB. Systemic therapy for stage I-III anal squamous cell carcinoma: ASCO Guideline. Journal of Clinical Oncology. 2025 Feb 10;43(5):605-15.
  • Krishnan T, Solar Vasconcelos JP, Titmuss E, Vanner RJ, Schaeffer DF, Karsan A, Lim H, Ho C, Gill S, Yip S, Chia SK, Kennecke HF, Jonker DJ, Chen EX, Renouf DJ, O’Callaghan CJ, Loree JM. Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors. Cancer research communications. 2025 Jan 9;5(1):66-73.
  • Casey M, Tozzi F, Wang J, Keon MinPark, Bergland, Hope T, Kennecke HF, Rose B, Babicky M, Irani S, El-Hayek K, Abu Hilal, Asbun H, Clearly S, Smeets P, Berrevoet F, Adam M, Rahidan N, Alseidi A. From diagnosis to treatment: navigating the course for pancreatic neuroendocrine neoplasms. Annals of Medicine. 2025 Dec 31;57(1):2569992
  • Zaidi A, Ravi P, Bloise I, Harsini S, Stuart HC, Kennecke HF, Alberts I, Bénard F, Wilson D, Martineau P, Loree JM. Dual PET Imaging with [68Ga] Ga-DOTA-TOC and [18F] FDG to Localize Neuroendocrine Tumors of Unknown Origin. Current Oncology. 2025 Sep 5;32(9):497.
  • Kennecke HF, Zell JA, Pham H, Simianu VV, Herz K, Kelley A, Carmichael JC, Hochster H, Kachnic LA. Results of a phase II trial of short-course radiation and TASOX [trifluridine/tipiracil (TAS-102) plus oxaliplatin] chemotherapy in operable rectal cancer. ESMO Gastrointestinal Oncology. 2025 Sep 1;9:100215.
  • Mittra ES, Wong RK, Winters C, Brown A, Murley S, Kennecke H. Establishing a robust radioligand therapy program: A practical approach for North American centers. Cancer medicine. 2024 Jan 12.
  • Loree JM, Titmuss E, Topham JT, Kennecke HF, Feilotter H, Virk S, Lee YS, Banks K, Quinn K, Karsan A, Renouf DJ. Plasma versus tissue tumor mutational burden as biomarkers of durvalumab plus tremelimumab response in patients with metastatic colorectal cancer in the CO. 26 trial. Clinical Cancer Research. 2024 May 10.
  • Wu FT, Topham JT, O'Callaghan CJ, Feilotter H, Kennecke HF, Drusbosky L, Renouf DJ, Jonker DJ, Tu D, Chen EX, Loree JM. Kinetic Profiling of RAS Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO. 26 Trial Suggests the Loss of RAS Mutations in Neo-RAS-Wildtype Metastatic Colorectal Cancer Is Transient. JCO Precision Oncology. 2024 Aug;8:e2400031.
  • Ma LX, Titmuss E, Loree JM, Jonker DJ, Kennecke HF, Berry S, Couture F, Ahmad CE, Goffin JR, Kavan P, Harb M. Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO. 26 trial. Journal for immunotherapy of cancer. 2024 Dec 4;12(12):e010094.
  • Kennecke HF, O'Callaghan CJ, Loree JM, Moloo H, Auer R, Jonker DJ, Raval M, Musselman R, Ma G, Caycedo-Marulanda A, Simianu VV. Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: the phase II NEO trial (CCTG CO. 28) primary end point results. Journal of Clinical Oncology. 2023 Jan 10;41(2):233-42.
  • Kennecke HF, Auer R, Cho M, Dasari NA, Davies-Venn C, Eng C, Dorth J, Garcia-Aguilar J, George M, Goodman KA, Kreppel L. NCI Rectal-Anal Task Force consensus recommendations for design of clinical trials in rectal cancer. JNCI: Journal of the National Cancer Institute. 2023 Dec 1;115(12):1457-64.
  • Chen EX, Loree JM, Titmuss E, Jonker DJ, Kennecke HF, Berry S, Couture F, Ahmad CE, Goffin JR, Kavan P, Harb M. Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients with Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Network Open. 2023 Dec 1;6(12):e2346094
  • Halfdanarson TR, Mallak N, Paulson S, Chandrasekharan C, Natwa M, Kendi AT, Kennecke HF. Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy. Cancers. 2023 Oct 2;15(19):4836.
  • Judge SJ, Ghalambor T, Cavnar MJ, Lidsky ME, Merkow RP, Cho M, Dominguez-Rosado I, Karanicolas PJ, Mayo SC, Rocha FG, Fields RC, Patel RA, Kennecke HF, Koerkamp BG, Yopp AC, Petrowsky H, Mahalingam D, Kemeny N, D'Angelica M, Gholami S. Current Practices in Hepatic Artery Infusion (HAI) Chemotherapy: An International Survey of the HAI Consortium Research Network. Ann Surg Oncol. 2023 Nov;30(12):7362-7370. doi: 10.1245/s10434-023-14207-7. Epub 2023 Sep 13. PMID: 37702903; PMCID: PMC11108096.
  • Boutin M, Topham JT, Feilotter H, Kennecke HF, Couture F, Harb M, Kavan P, Berry S, Lim HJ, Goffin JR, Ahmad C. Optimizing the number of variants tracked to follow disease burden with circulating tumor DNA assays in metastatic colorectal cancer. Therapeutic Advances in Medical Oncology. 2023 Jun;15:17588359231183682.
  • Su P, Pedraza R, Kennecke H. Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer. DOI: 10.3390/curroncol30040279. Curr. Oncol. 2023, 30(4), 3672-3683; https://doi.org/10.3390/curroncol30040279.
  • Del-Rivero J, Mailman J, Radow MW, Chan JA, Creed S, Kennecke H, Pasieka J, Zuar J, Singh S, Fishbein L. Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care. doi: 10.1530/ERC-22-0226/Endocr Relat Cancer. 2023 Apr 1;ERC-22-0226.
  • Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, Goldberg J, Baghdadi TA, Goodman KA, McWilliams RR, Farma JM, George TJ, Kennecke HF, Shergill A, Montemurro M, Nelson GD, Colgrove B, Gordon V, Venook AP, O’Reilly EM, Meyerhardt JA, Dueck AC, Basch E, Change GJ, Mamon HJ. Preoperative Treatment of Locally Advanced Rectal Cancer. DOI: 10.1056/NEJMoa2303269 PMID: 37272534, N Engl J Med 2023 Jun 4. Online ahead of print.
  • Chen L, Speers CH, WY, Spinelli JJ, Kennecke HF. Impact of new cancer therapies on outpatient treatment delivery for colorectal cancer: A population-based study. Int J Health Plann Manage. 2022 Jan;37(1):258-270. doi: 10.1002/hpm.3308. Epub 2021 Sep 20. PubMed PMID: 34545610.
  • Naveed Ahmad JA, Schroeder BB, Ruhoy, SM, Kennecke HF, Lin BS. Severe Thrombocytopenia in Patients with Advanced Neuroendocrine Tumor Treated with Peptide Receptor Radioligand Therapy. Clin Nucl Med. 2022 May 1;47(5):409-413. doi: 10.1097/RLU.0000000000004130. PubMed PMID: 35307721; PubMed Central PMCID: PMC8983945.
  • Bakouny Z, B, Berg S, Bilen MA, Bowles D, Castellano C, Desai A, Elkrief A, Eton OE, Fecher LA, Flora D, Galsky MD, Gatti-Mays ME, Gesenhues A, Glover MJ, Gopalakrishnan D, Gupta S, Halfdanarson TR, Hayes-Lattin B, Hendawi M, Hsu E, Hwang C, Jandarov R, Jani C, Kulke MH, Ou FS, Niedzwiecki D, Huebner L, Kunz P, Kennecke HF, Wolin EM, Chan JA, O’Reilly EM, Meyerhardt JA, Vennok A. Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). May 9;29(6):335-344. doi: 10.1530/ER
  • Soriano C, Bahnson HT, Kaplan JA, Lin B, Moonka R, Pham HT, Kennecke HF, Simianu V. Contemporary, national patterns of surgery after preoperative therapy for stage II/III rectal adenocarcinoma. World J Gastrointest Oncol. 2022 Jun 15;14(6):1148-1161. doi: 10.4251/wjgo.v14.i6.1148. PubMed PMID: 35949222; PubMed Central PMCID: PMC9244989.
  • Kennecke HF, Bahnson HT, Li B, et al. Patterns of Practice and Improvements in Survival Among Patients with Stage 2/3 Rectal Cancer Treated with Trimodality Therapy. JAMA Oncol. Published online August 18, 2022. doi:10.1001/jamaoncol.2022.2831.
  • Topham JT, O'Callaghan CJ, Feilotter H, Kennecke HF, Lee YS, Li W, Banks KC, Quinn K, Renouf DJ, Jonker DJ, TD, Chen EX, Loree JM. Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer. J Clin Oncol. 2022 Aug 25:JCO2200364. doi: 10.1200/JCO.22.00364. Epub ahead of print. PMID: 36007218.